human anti-d immunoglobulin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
human anti-d immunoglobulin: clinical details
Prescribing considerations
- Confirm RhD status and whether immune anti-D is already present before prophylaxis.
- Assess the likely extent of RhD-positive red-cell exposure; significant fetomaternal haemorrhage or incompatible transfusion requires specialist assessment.
- Select a route and product appropriate for haemostasis, body habitus and the urgency of achieving circulating antibody levels.
- Record the product name and batch number because this is a plasma-derived biological medicine.
Contraindications and cautions
- Hypersensitivity to human anti-D immunoglobulin, human immunoglobulins or product excipients.
- D-Gam is not intended for RhD-positive individuals and requires particular caution where IgA deficiency with anti-IgA antibodies is suspected.
- Intramuscular Rhophylac is contraindicated in severe thrombocytopenia or other haemostatic disorders; D-Gam should not be used when intramuscular administration is contraindicated.
- Rhophylac is not intended for people already immunised to the RhD antigen.
Monitoring
- Observe for hypersensitivity during and after administration; stop immediately if an allergic or anaphylactic reaction is suspected.
- After incompatible transfusion, monitor clinically and with appropriate laboratory markers for haemolysis and clearance of RhD-positive red cells.
- Consider testing to quantify fetomaternal haemorrhage when substantial exposure is suspected.
- Interpret antibody screens and antiglobulin tests in the context of recent passive anti-D administration.
Clinical pharmacology
Human anti-D immunoglobulin supplies anti-RhD IgG for passive immunisation. Intravenous administration gives immediate systemic availability, while intramuscular absorption is slower. IgG and immune complexes are cleared through the reticuloendothelial system.
Formulation and product differences
- D-Gam is supplied in single-use vials for intramuscular injection; the labelled withdrawal volume reflects batch potency. It contains a small quantity of IgA.
- Rhophylac is a ready-to-use pre-filled syringe for intravenous or intramuscular administration. It contains human albumin as a stabiliser, trace IgA and no preservative.
- Consider an intravenous-capable product when intramuscular administration is unsuitable or may be unreliable, including significant haemostatic disorders or obesity.
human anti-d immunoglobulin preparations and strengths
Injection
Route: Parenteral
Strengths: 50 micrograms/mL, 250 micrograms/mL
human anti-d immunoglobulin interactions
Tell the healthcare team about recent vaccinations and planned blood tests.
Live attenuated viral vaccines, including MMR and varicella vaccines
Anti-D immunoglobulin may reduce the vaccine response, so the vaccination team may need to adjust timing or confirm protection.
Inactivated pregnancy vaccines
Injected influenza, pertussis-containing and RSV vaccines can be administered alongside anti-D immunoglobulin when otherwise indicated.
Serological and red-cell antibody tests
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.